Rua Bioscience reports record six month sales

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com





FOR PUBLIC RELEASE

NZX Limited
Wellington

30 April 2025

Rua Bioscience reports record sales across key markets with strong six-month results

Rua Bioscience has achieved unaudited revenue of $900k for the six months ending
March 31, 2025 which is a significant increase of 235% over the previous six month
period. This reflects a significant acceleration of our growth across Germany, New
Zealand, and Australia.




Highlights
For the six months ending March 2025, Rua achieved unaudited revenue of $900k, up
significantly from $268k for the previous 6-month period. This exceptional result reflects
robust demand across all core markets and validates Rua’s strategy of building a strong
export-led business rooted in quality and world-class cultivation and manufacturing
partners.
268
900
6 month
Apr 24 - Sept 24
6month
Oct 24 - Mar 25
Sales revenue
(Unaudited, NZ$ 000)
MARKET UPDATE

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
Our momentum in the third quarter (January to March 2025) has been particularly
encouraging:
Germany: Rua recorded record sales for the latest quarter, driven by high demand for
our medicinal cannabis flower products. Current demand continues to outstrip supply,
highlighting the trusted reputation Rua is building with Nimbus Healthcare and German
prescribers and patients. We are actively working to expand supply capacity to meet this
growing need.
New Zealand: Sales at home also reached new records for the most recent quarter,
following ongoing product launches and broadening patient access. Our expansion of
products is contributing to strong month-on-month growth, further establishing Rua as a
key player in Aotearoa’s rapidly maturing medicinal cannabis sector.
Australia: Sales remain steady as we strategically adjust our portfolio to meet evolving
market demands. Recent supply constraints have limited short-term growth, but new
supply and products in the pipeline are set to reignite momentum.
Focused execution on Rua’s strategy
CEO Paul Naske commented that, "Achieving $900,000 in revenue in six months as a
start-up company is an outstanding milestone. It demonstrates the success of our
strategy, the quality of our products, and the hard work of our team. Most importantly, it
brings us closer to fulfilling our purpose of changing lives both here at home and
internationally."
Rua Bioscience's strategy remains clear: develop and commercialize premium New
Zealand-grown medicinal cannabis, establish strong distribution channels in high-growth
international markets, and unlock scalable, sustainable value for shareholders and
communities.
Outlook
Rua’s strong performance in the six months to March 2025 sets a solid foundation for the
remainder of FY25 and beyond. With demand trends firmly positive, Rua will focus on:
• Expanding supply capacity for the German market.
• Launching new products into New Zealand and Germany.
• Early-stage opportunities in the Czechia.
• Deepening relationships and sales with key clinics in the UK.
• Further embedding Rua genetics internationally, with early-stage opportunities in
Canada and Portugal.
We are confident Rua Bioscience is entering its next phase of growth, supported by a
clear vision, world-class products, and the energy of a passionate team.
We thank our shareholders for their continued support and look forward to updating you
on our progress as we continue to grow.

ENDS  

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
 
The person who authorised this announcement:

Paul Naske
Chief Executive Officer
paul.naske@ruabio.com

+64 21 445154